SG11201901689YA - Compounds for treating diseases associated with a mitochondrial dysfonction - Google Patents

Compounds for treating diseases associated with a mitochondrial dysfonction

Info

Publication number
SG11201901689YA
SG11201901689YA SG11201901689YA SG11201901689YA SG11201901689YA SG 11201901689Y A SG11201901689Y A SG 11201901689YA SG 11201901689Y A SG11201901689Y A SG 11201901689YA SG 11201901689Y A SG11201901689Y A SG 11201901689YA SG 11201901689Y A SG11201901689Y A SG 11201901689YA
Authority
SG
Singapore
Prior art keywords
international
paris
mitochondrial
dysfonction
compounds
Prior art date
Application number
SG11201901689YA
Inventor
Antoine Danchin
Agnieszka Sekowska
Patrice Garnier
Original Assignee
Amabiotics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amabiotics filed Critical Amabiotics
Publication of SG11201901689YA publication Critical patent/SG11201901689YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 1110101011111 011101 0 011111111 0111111110111110111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/041919 Al 08 March 2018 (08.03.2018) W I P0 I P C T (51) International Patent Classification: A61K 31/519 (2006.01) A61P 25/16 (2006.01) Published: A61K 31/7068 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: PCT/EP2017/071812 (22) International Filing Date: 30 August 2017 (30.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16306094.0 30 August 2016 (30.08.2016) EP (71) Applicant: AMABIOTICS [FR/FR]; 47 RUE DE MONT- MORENCY, 75003 PARIS (FR). (72) Inventors: DANCHIN, Antoine; 86 rue Brillat-Savarin, 75003 Paris (FR). SEKOWSKA, Agnieszka; 86 me Bril- lat-Savarin, 75003 Paris (FR). GARNIER, Patrice; San Po- lo 1865, 30125 Venezia (IT). Agent: VIAL, Lionel; 6 me de Vaugondran, 91190 Gif sur (74) = Yvette (FR). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (81) = _ = __ _ HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, _ = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every (84) kind of regional protection available): ARIPO (BW, GH, = _ _ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, — TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = 1-1 (54) Title: COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFONCTION 0\ (57) : The present invention relates to a compound of the following formula (A): or a pharma- 1-1 R12 ceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of a disease associated 1-1 NH 0 with a mitochondrial dysfunction. 71' 0 ......... (A) / NH 1-1 -;:- 0 N N / N..--..,, NH2 Ri
SG11201901689YA 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction SG11201901689YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306094.0A EP3290039B1 (en) 2016-08-30 2016-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction
PCT/EP2017/071812 WO2018041919A1 (en) 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction

Publications (1)

Publication Number Publication Date
SG11201901689YA true SG11201901689YA (en) 2019-03-28

Family

ID=56896495

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901689YA SG11201901689YA (en) 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction

Country Status (15)

Country Link
US (2) US10857135B2 (en)
EP (2) EP3290039B1 (en)
JP (1) JP7065854B2 (en)
KR (1) KR20200011927A (en)
CN (1) CN110035758B (en)
AU (1) AU2017317651B2 (en)
BR (1) BR112019004236A2 (en)
CA (1) CA3034694A1 (en)
ES (1) ES2800917T3 (en)
MA (1) MA46099A (en)
MX (1) MX2019002369A (en)
RU (1) RU2019108824A (en)
SG (1) SG11201901689YA (en)
WO (1) WO2018041919A1 (en)
ZA (1) ZA201900997B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction
CA3093212A1 (en) * 2018-03-07 2019-09-12 Amabiotics Compounds for treating alzheimer's disease
WO2020160183A1 (en) * 2019-01-29 2020-08-06 Holobiome, Inc. Methods and compositions for treating and preventing cns disorders and other conditions caused by gut microbial dysbiosis
EP4028014A1 (en) * 2019-09-12 2022-07-20 Stellate Therapeutics Compounds for treating neurodegenerative diseases
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936615A (en) * 1982-08-24 1984-02-28 Takeda Chem Ind Ltd Carcinostatic agent
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
EP1221615A2 (en) * 1995-04-25 2002-07-10 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
FR3002139B1 (en) * 2013-02-21 2015-06-19 Amabiotics COSMETIC USE OF QUEUINE
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction

Also Published As

Publication number Publication date
US20190224174A1 (en) 2019-07-25
WO2018041919A1 (en) 2018-03-08
CN110035758B (en) 2023-06-16
BR112019004236A2 (en) 2019-05-28
AU2017317651B2 (en) 2022-12-15
RU2019108824A (en) 2020-10-01
EP3290039A1 (en) 2018-03-07
KR20200011927A (en) 2020-02-04
CA3034694A1 (en) 2018-03-08
MX2019002369A (en) 2019-11-07
US11684611B2 (en) 2023-06-27
ZA201900997B (en) 2020-05-27
CN110035758A (en) 2019-07-19
EP3506903A1 (en) 2019-07-10
JP7065854B2 (en) 2022-05-12
US10857135B2 (en) 2020-12-08
EP3290039B1 (en) 2020-03-25
MA46099A (en) 2019-07-10
JP2019526634A (en) 2019-09-19
US20210046056A1 (en) 2021-02-18
RU2019108824A3 (en) 2020-12-31
ES2800917T3 (en) 2021-01-05
AU2017317651A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201903487SA (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201907034PA (en) Methods of treating influenza
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901633WA (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
SG11201808108XA (en) Synthesis of indazoles
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201808686VA (en) Synthesis of indazoles
SG11201805755SA (en) Methods of administering hepcidin
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor